According to Novavax Inc, its experimental vaccine against COVID-19 exhibited immune response and protection against the highly contagious variant of the coronavirus that was first detected in South Africa, in a new study.

NVX-CoV2373, Novavax’s vaccine against COVID-19, is being tested in several trials and is yet to receive authorization for use in any country. Novavax stated that trials in mice and baboons noted that a different vaccine which particularly targets the Beta variant produced immune response and protection. The company expects to carry out further clinical testing of the vaccine in the fall.

Analysis of blood serum of 30 participants in a mid-stage trial who had been administered both doses of NVX-CoV2373 noted robust antibody responses against the original version of the virus and against the Alpha variant first found in the UK as well as the Beta variant… (Reuters, June 12, 2021)